Gene info: ID 1816

Gene: DRD5

GENE ID: 1816

Synonyms: DBDR|DRD1B|DRD1L2

Description: dopamine receptor D5

Gene type: protein-coding

Location: 4p16.1

dbXrefs: Ensembl:ENSG00000169676 MIM:126453 Vega:OTTHUMG00000128489 UniprotKB:P21918

RefSeq: NG_012024.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: CD|ND|AD

# Publications: 8

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 3.279e-1 (AD) 5.898e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
GALNT14	0.831
GRIK3	0.806
ADTRP	0.799
SLC7A4	0.792
CNIH3	0.787
CPNE7	0.787
CLSTN2	0.786
NRG1	0.785
IL12RB2	0.777
RAB3B	0.775

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PRKD3	-0.574
EPS8	-0.568
RBPMS	-0.568
GNG11	-0.559
WWTR1	-0.559
RAB13	-0.555
YES1	-0.548
TEAD3	-0.547
RNF135	-0.547
CLEC2B	-0.546

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00246	Ziprasidone	Small Molecule	146939-27-7	Approved	Target
DB00248	Cabergoline	Small Molecule	81409-90-7	Approved	Target
DB00268	Ropinirole	Small Molecule	91374-21-9	Approved\|Investigational	Target
DB00334	Olanzapine	Small Molecule	132539-06-1	Approved\|Investigational	Target
DB00408	Loxapine	Small Molecule	1977-10-2	Approved	Target
DB00413	Pramipexole	Small Molecule	104632-26-0	Approved\|Investigational	Target
DB00477	Chlorpromazine	Small Molecule	50-53-3	Approved\|Investigational	Target
DB00589	Lisuride	Small Molecule	18016-80-3	Approved\|Investigational	Target
DB00714	Apomorphine	Small Molecule	58-00-4	Approved\|Investigational	Target
DB00800	Fenoldopam	Small Molecule	67227-56-9	Approved	Target
DB00988	Dopamine	Small Molecule	51-61-6	Approved	Target
DB01038	Carphenazine	Small Molecule	2622-30-2	Withdrawn	Target
DB01186	Pergolide	Small Molecule	66104-22-1	Approved\|Investigational\|Withdrawn	Target
DB01200	Bromocriptine	Small Molecule	25614-03-3	Approved\|Investigational	Target
DB01224	Quetiapine	Small Molecule	111974-69-7	Approved	Target
DB01235	Levodopa	Small Molecule	59-92-7	Approved	Target
DB01238	Aripiprazole	Small Molecule	129722-12-9	Approved\|Investigational	Target
DB01403	Methotrimeprazine	Small Molecule	60-99-1	Approved\|Investigational	Target
DB01624	Zuclopenthixol	Small Molecule	53772-83-1	Approved\|Investigational	Target
DB05271	Rotigotine	Small Molecule	99755-59-6	Approved	Target
DB00248	Cabergoline	Small Molecule	81409-90-7	Approved	Target
DB00334	Olanzapine	Small Molecule	132539-06-1	Approved\|Investigational	Target
DB00370	Mirtazapine	Small Molecule	85650-52-8	Approved	Target
DB00408	Loxapine	Small Molecule	1977-10-2	Approved	Target
DB00458	Imipramine	Small Molecule	50-49-7	Approved	Target
DB00477	Chlorpromazine	Small Molecule	50-53-3	Approved\|Investigational	Target
DB00555	Lamotrigine	Small Molecule	84057-84-1	Approved\|Investigational	Target
DB00568	Cinnarizine	Small Molecule	298-57-7	Approved\|Investigational	Target
DB00696	Ergotamine	Small Molecule	113-15-5	Approved	Target
DB00726	Trimipramine	Small Molecule	739-71-9	Approved	Target
DB00988	Dopamine	Small Molecule	51-61-6	Approved	Target
DB06148	Mianserin	Small Molecule	24219-97-4	Approved\|Investigational	Target
DB09097	Quinagolide	Small Molecule	87056-78-8	Approved\|Investigational	Target
DB09225	Zotepine	Small Molecule	26615-21-4	Approved\|Investigational\|Withdrawn	Target

ID	Drug Name	Action	PubMed
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	"2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of DRD5 protein"	26215117
C023514	2,6-dinitrotoluene	"2,6-dinitrotoluene affects the expression of DRD5 mRNA"	21346803
C409874	7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine	"7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine binds to and results in decreased activity of DRD5 protein"	12447918\|1518390
C409874	7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine	"7-methyl-6,7,8,9,14,15-hexahydro-5H-benz(d)indolo(2,3-g)azecine binds to DRD5 protein"	21888437
C065380	A 68930	A 68930 binds to and results in increased activity of DRD5 protein	14960337
C065380	A 68930	[A 68930 binds to and results in increased activity of DRD5 protein] which affects the susceptibility to Amphetamine	14960337
C095427	A 86929	A 86929 promotes the reaction [DRD5 protein results in increased chemical synthesis of Cyclic AMP]	8558425
C095427	A 86929	A 86929 binds to DRD5 protein	8558425
C095427	A 86929	A 86929 results in increased activity of DRD5 protein	8558425
D000242	Cyclic AMP	A 86929 promotes the reaction [DRD5 protein results in increased chemical synthesis of Cyclic AMP]	8558425
D000336	Aerosols	Aerosols results in increased expression of DRD5 mRNA	25265048
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of DRD5 mRNA	22100608
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of DRD5 gene	28458013
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of DRD5 mRNA	16483693
D000661	Amphetamine	[A 68930 binds to and results in increased activity of DRD5 protein] which affects the susceptibility to Amphetamine	14960337
D000661	Amphetamine	[dihydrexidine binds to and results in increased activity of DRD5 protein] which affects the susceptibility to Amphetamine	14960337
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of DRD5 mRNA	24449571
C006780	bisphenol A	bisphenol A results in decreased expression of DRD5 mRNA	25181051\|2614162
C018475	butyraldehyde	butyraldehyde results in increased expression of DRD5 mRNA	26079696
D002104	Cadmium	Cadmium results in decreased expression of DRD5 mRNA	24376830
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in increased expression of DRD5 mRNA	21472459
D020111	Chlorodiphenyl (54% Chlorine)	Quercetin inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in increased expression of DRD5 mRNA]	21472459
C018021	cobaltous chloride	cobaltous chloride results in increased expression of DRD5 mRNA	19376846
D003042	Cocaine	Cocaine affects the expression of DRD5 mRNA	20187946
D019327	Copper Sulfate	Copper Sulfate results in increased expression of DRD5 mRNA	19549813
D003471	Cuprizone	Cuprizone results in decreased expression of DRD5 mRNA	26577399
C010902	decabromobiphenyl ether	decabromobiphenyl ether results in decreased expression of DRD5 mRNA	23640034
D001728	Dicumarol	Dicumarol results in increased expression of DRD5 mRNA	18522901
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of DRD5 mRNA	21658437
C061532	dihydrexidine	dihydrexidine binds to and results in increased activity of DRD5 protein	14960337
C061532	dihydrexidine	[dihydrexidine binds to and results in increased activity of DRD5 protein] which affects the susceptibility to Amphetamine	14960337
D004298	Dopamine	Dopamine results in increased expression of DRD5 mRNA	18522901
C058081	ecopipam	ecopipam binds to and results in decreased activity of DRD5 protein	10591286
D005419	Flavonoids	Flavonoids results in decreased expression of DRD5 mRNA	18035473
D005472	Fluorouracil	DRD5 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]	17327601
D002955	Leucovorin	DRD5 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]	17327601
C069837	fullerene C60	fullerene C60 results in decreased expression of DRD5 mRNA	19167457
C051890	irinotecan	DRD5 mRNA results in increased susceptibility to [Leucovorin co-treated with Fluorouracil co-treated with irinotecan]	17327601
C045463	leflunomide	leflunomide results in increased expression of DRD5 mRNA	28988120
D008344	Maneb	[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA	23017109
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of DRD5 mRNA"	20188158
D008825	Miconazole	Miconazole results in increased expression of DRD5 mRNA	22262564
C028007	nickel monoxide	nickel monoxide results in decreased expression of DRD5 mRNA	19167457
D010269	Paraquat	[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA	23017109
D052638	Particulate Matter	[Particulate Matter co-treated with Volatile Organic Compounds] results in increased expression of DRD5 mRNA	25265048
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid affects the expression of DRD5 mRNA	26686188
D010627	Phenethylamines	Phenethylamines analog binds to DRD5 protein	16539400
D010936	Plant Extracts	Plant Extracts results in decreased expression of DRD5 mRNA	23557933
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of DRD5 mRNA	23608068
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of DRD5 mRNA	24780913
D011794	Quercetin	Quercetin inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in increased expression of DRD5 mRNA]	21472459
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride results in increased expression of DRD5 mRNA	19429434
D012524	Sarin	Sarin results in increased expression of DRD5 mRNA	19522546
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of DRD5 mRNA	23806026
D013629	Tamoxifen	Tamoxifen affects the expression of DRD5 mRNA	14699072
D013629	Tamoxifen	Tamoxifen results in increased expression of DRD5 mRNA	19429434
D013806	Theophylline	Theophylline results in increased expression of DRD5 mRNA	18951874
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of DRD5 mRNA"	26179874
D014635	Valproic Acid	Valproic Acid results in increased methylation of DRD5 gene	29154799
D055549	Volatile Organic Compounds	[Particulate Matter co-treated with Volatile Organic Compounds] results in increased expression of DRD5 mRNA	25265048

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001588	dopamine neurotransmitter receptor activity, coupled via Gs	-	IBA	21873635
GO:0001588	dopamine neurotransmitter receptor activity, coupled via Gs	-	TAS	9457173
GO:0001965	G-protein alpha-subunit binding	-	IBA	21873635
GO:0004952	dopamine neurotransmitter receptor activity	-	IDA	1826762
GO:0035240	dopamine binding	-	IBA	21873635
GO:0035240	dopamine binding	-	IDA	1826762

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001963	synaptic transmission, dopaminergic	-	NAS	11036203
GO:0001975	response to amphetamine	-	IEA	-
GO:0001992	regulation of systemic arterial blood pressure by vasopressin	-	IEA	-
GO:0001994	norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	-	IEA	-
GO:0006874	cellular calcium ion homeostasis	-	TAS	9457173
GO:0007186	G-protein coupled receptor signaling pathway	-	TAS	-
GO:0007189	adenylate cyclase-activating G-protein coupled receptor signaling pathway	-	IDA	11500503
GO:0007190	activation of adenylate cyclase activity	-	TAS	9457173
GO:0007191	adenylate cyclase-activating dopamine receptor signaling pathway	-	IBA	21873635
GO:0007191	adenylate cyclase-activating dopamine receptor signaling pathway	-	IDA	1826762 18403039
GO:0007268	chemical synaptic transmission	-	NAS	7727453
GO:0008306	associative learning	-	IEA	-
GO:0019226	transmission of nerve impulse	-	IEA	-
GO:0033861	negative regulation of NAD(P)H oxidase activity	-	IDA	16352863
GO:0042060	wound healing	-	IEA	-
GO:0042220	response to cocaine	-	IEA	-
GO:0045762	positive regulation of adenylate cyclase activity	-	NAS	7727453
GO:0045776	negative regulation of blood pressure	-	IEA	-
GO:0045924	regulation of female receptivity	-	IEA	-
GO:0046960	sensitization	-	IEA	-
GO:0060158	phospholipase C-activating dopamine receptor signaling pathway	-	TAS	9457173
GO:0060292	long term synaptic depression	-	IEA	-
GO:0071870	cellular response to catecholamine stimulus	-	IDA	18403039
GO:0072593	reactive oxygen species metabolic process	-	IDA	16352863

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005622	intracellular	-	IEA	-
GO:0005886	plasma membrane	-	IBA	21873635
GO:0005886	plasma membrane	-	IDA	10531415 11500503
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	NAS	1826762
GO:0005887	integral component of plasma membrane	-	TAS	9457173
GO:0016021	integral component of membrane	-	IBA	21873635
GO:0031526	brush border membrane	-	IEA	-
GO:0060170	ciliary membrane	-	IDA	20531939
GO:0097730	non-motile cilium	-	IDA	20531939

KEGG ID	KEGG Term
hsa04020	Calcium signaling pathway
hsa04080	Neuroactive ligand-receptor interaction

Reactome ID	Reactome Term	Evidence
R-HSA-162582	Signal Transduction	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	TAS
R-HSA-375280	Amine ligand-binding receptors	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-390651	Dopamine receptors	TAS
R-HSA-418555	G alpha (s) signalling events	TAS
R-HSA-500792	GPCR ligand binding	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
11353446	An association study of DRD5 with smoking initiation and progression to nicotine dependence. (2001 Apr 8)	Sullivan PF	Am J Med Genet
9686426	Chromosome 4 workshop. (1998 Summer)	Kennedy JL	Psychiatr Genet
17579368	Testing for gene x environment interaction effects in attention deficit hyperactivity disorder and associated antisocial behavior. (2008 Jan 5)	Langley K	Am J Med Genet B Neuropsychiatr Genet
25875614	Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans. (2015 May)	Levran O	Ann Hum Genet
22309839	Association study of 45 candidate genes in nicotine dependence in Han Chinese. (2012 May)	Wei J	Addict Behav
19179847	Genetics of dopamine receptors and drug addiction: a comprehensive review. (2009 Feb)	Le Foll B	Behav Pharmacol
17466946	5' UTR polymorphism of dopamine receptor D1 (DRD1) associated with severity and temperament of alcoholism. (2007 Jun 15)	Kim DJ	Biochem Biophys Res Commun
21083670	Limited associations of dopamine system genes with alcohol dependence and related traits in the Irish Affected Sib Pair Study of Alcohol Dependence (IASPSAD). (2011 Feb)	Hack LM	Alcohol Clin Exp Res